'A new era of medicine': In a first for CRISPR, Intellia edits cells inside the body

In a first for the still-young field of CRISPR gene editing, Intellia Therapeutics (Nasdaq: NTLA) has successfully edited DNA inside the human body. The Cambridge biotech, working with Regeneron Pharmaceuticals (Nasdaq: RGEN), genetically altered liver cells in six patients with a genetic nerve disorder called transthyretin amyloidosis in a Phase 1 study. On Saturday, Intellia and Regeneron published data showing that the treatment had reduced levels of a disease-causing protein by 52% at a relatively…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news